KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01). PMID 37328835 · BMC Cancer · 2023-Jun-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Randomized Trial. PMID 37318875 · JMIR Res Protoc · 2023-Jun-15 The record is a protocol for a study, not a results report. It lacks explicit Phase III/IIIb or Phase II/III classification, and the primary and key secondary outcomes are process measures and recurrence rate (not time-to-event). Therefore, it does not meet eligibility criteria for original formal-result reports of randomized trials with time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multi-centre randomized controlled trial investigating Consolidation Chemotherapy with and without oxaliplatin in distal rectal cancer and Watch & Wait. PMID 37316784 · BMC Cancer · 2023-Jun-14 The record describes a protocol for a randomized trial in human rectal cancer with a drug intervention (oxaliplatin), but it lacks reported results for a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) as required. The primary endpoint is a decision (organ-preservation surveillance), not a time-to-event outcome. The phase is not explicitly stated as Phase III or definitive (only registration information is provided).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN-A Randomized Trial with Low Molecular Weight Heparin. PMID 37370786 · Cancers (Basel) · 2023-Jun-13 The report is a sub-study of the RASTEN trial focusing on circulating tumor cells as a prognostic biomarker, not the primary efficacy report of the randomized trial. The abstract does not explicitly state the trial phase as Phase III/IIIb or Phase II/III. Therefore, it does not meet the inclusion criteria for a primary trial report with definitive phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The therapeutic potential of purified cannabidiol. PMID 37312194 · J Cannabis Res · 2023-Jun-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial. PMID 37312054 · BMC Cancer · 2023-Jun-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial. PMID 37312053 · BMC Cancer · 2023-Jun-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy. PMID 37310167 · Cochrane Database Syst Rev · 2023-Jun-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. PMID 37266947 · JAMA · 2023-Jun-13 The study is a randomized controlled trial in an oncology population with a drug intervention, but it does not meet the core requirement of having a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) analyzed via Kaplan-Meier or HR. The primary endpoint is the recurrent VTE rate at 6 months, a cumulative incidence measure, not a standard time-to-event endpoint for this cohort's definition. Phase is not explicitly stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. PMID 37022350 · Clin Cancer Res · 2023-Jun-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity. PMID 37014666 · Clin Cancer Res · 2023-Jun-13 The record describes a secondary or subgroup analysis of a biomarker (cell-free DNA) within a randomized trial (GOELAMS 075). While the study is oncologic, involves humans, is randomized, includes drug interventions, and reports time-to-event outcomes (OS), it is not an original, formal report of the trial's primary or key secondary efficacy results. The analysis is specifically on the prognostic value of baseline cfDNA and its interaction with treatment intensity, making it a secondary/biomarker subgroup analysis. Furthermore, the parent trial's phase (III/IIIb or II/III) is not explicitly confirmed in the provided metadata, though the trial name and design suggest it may be a definitive trial. The exclusion is based on the report type being secondary/biomarker-focused and the lack of explicit phase confirmation for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Standard Hypercaloric, Hyperproteic vs. Leucine-Enriched Oral Supplements in Patients with Cancer-Induced Sarcopenia, a Randomized Clinical Trial. PMID 37375630 · Nutrients · 2023-Jun-12 The study is an original RCT in cancer patients, but it does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The intervention is dietary/nutritional supplements, not a drug. The trial phase is not explicitly stated as Phase III or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease. PMID 37308971 · Breast Cancer Res · 2023-Jun-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors. PMID 37301885 · Nat Commun · 2023-Jun-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An eHealth symptom and complication management program for cancer patients with newly created ostomies and their caregivers (Alliance): a pilot feasibility randomized trial. PMID 37301841 · BMC Cancer · 2023-Jun-10 The record is a pilot feasibility randomized controlled trial of a non-drug eHealth intervention. It is not a definitive Phase III/IIIb or Phase II/III trial, lacks a drug-containing intervention, and does not report a time-to-event efficacy endpoint (Kaplan-Meier or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. PMID 37104748 · J Clin Oncol · 2023-Jun-10 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. PMID 37104723 · J Clin Oncol · 2023-Jun-10 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial. PMID 37365597 · Radiat Oncol · 2023-Jun-09 The study is an eligible Phase III RCT with a drug intervention, but its primary endpoint is hematological toxicity (a safety/toxicity endpoint), not a time-to-event efficacy endpoint required for the cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Use of focal radiotherapy boost for prostate cancer and perceived barriers toward its implementation: a survey. PMID 37333345 · medRxiv · 2023-Jun-08 The record is a survey about barriers to implementing a radiotherapy technique from a referenced trial, not the original trial report. It lacks a drug intervention and does not report time-to-event efficacy endpoints. Therefore, it is not eligible for inclusion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. PMID 35094066 · J Natl Cancer Inst · 2023-Jun-08 The record describes a randomized trial with drug intervention (TKI) and time-to-event efficacy endpoints (PFS, OS) with original interim results. However, the trial phase is not explicitly stated in the title, abstract, or metadata, and the abstract context (first-generation TKI, oligometastatic NSCLC, and trial design) suggests it may be Phase II rather than the required Phase III/IIIb or Phase II/III. The deterministic review also notes the phase is unclear. Without explicit confirmation of Phase III/IIIb or Phase II/III, the eligibility criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A nomogram for predicting cancer-specific survival in patients with uterine clear cell carcinoma: a population-based study. PMID 37286668 · Sci Rep · 2023-Jun-07 While the study is oncologic, human, and uses randomization for model building, it is not a definitive Phase III/IIIb or Phase II/III randomized trial of a drug intervention. The primary objective is nomogram development for prognostic prediction, not evaluation of a drug's efficacy via a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Alemtuzumab for multiple sclerosis. PMID 37272540 · Cochrane Database Syst Rev · 2023-Jun-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of modified radical laparoscopic hysterectomy versus open radical hysterectomy on short-term clinical outcomes in early-stage cervical cancer: a single-center, prospective, randomized controlled trial. PMID 37270549 · World J Surg Oncol · 2023-Jun-03 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial. PMID 37146623 · Lancet · 2023-Jun-03 The study is a randomized, phase 3 clinical trial for chronic low back pain, not an oncology trial. It does not involve a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pragmatica-Lung Trial to Mimic "Real-World" Conditions. PMID 37068201 · Cancer Discov · 2023-Jun-02 The abstract describes the design of a Phase III randomized trial (Pragmatica-Lung) but does not report results, including any time-to-event efficacy endpoints (OS, PFS, etc.) or specific drug interventions. It is a protocol/design paper, not an original formal-result report of a trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. PMID 36940261 · Oncologist · 2023-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. PMID 36472389 · Neuro Oncol · 2023-Jun-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effectiveness of Scapular Strengthening Exercises on Shoulder Dysfunction for Pain and Functional Disability after Modified Radical Mastectomy: A Controlled Clinical Trial. PMID 37378941 · Asian Pac J Cancer Prev · 2023-Jun-01 This is a randomized controlled trial in breast cancer patients, but the intervention is exercise-based (scapular strengthening), not a drug-containing regimen. Furthermore, the primary outcomes are pain, functional disability, and shoulder range of motion, not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or disease-free survival. Therefore, it does not meet the inclusion criteria for a drug-containing oncology Phase III/IIIb or Phase II/III randomized trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of a Nurse Navigation Intervention on Mental Symptoms in Patients With Psychological Vulnerability and Breast Cancer: The REBECCA Randomized Clinical Trial. PMID 37351885 · JAMA Netw Open · 2023-Jun-01 The study is a randomized, oncology trial with original results, but it does not meet the core eligibility criteria: the intervention is a nurse navigation program (non-drug), and the endpoints are not time-to-event efficacy measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery. PMID 37351147 · Hepatobiliary Surg Nutr · 2023-Jun-01 The record describes a retrospective, single-arm study evaluating safety and outcomes of a downstaging therapy followed by surgery. It is not a randomized trial and does not establish a definitive Phase III or Phase II/III trial context. While it includes a drug intervention (Y90) and reports time-to-event endpoints, it fails the core requirement of being a randomized trial with a definitive late-phase design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission. PMID 37263700 · BMJ Open · 2023-Jun-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. PMID 37261831 · JAMA Netw Open · 2023-Jun-01 The study is a randomized, prospective trial with a time-to-event endpoint (OS) and drug intervention, meeting oncology, human, randomized, time_to_event, drug_intervention, and original_result criteria. However, the trial phase is not explicitly stated in the abstract or metadata as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. PMID 37259799 · Cancer Prev Res (Phila) · 2023-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial. PMID 37219875 · Hepatol Commun · 2023-Jun-01 The record is a subgroup analysis of the SORAMIC trial, not the primary or definitive report of the trial's main results. The inclusion criteria require the original formal-result report of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ERAS Protocol Applied to Oncological Colorectal Mini-invasive Surgery Reduces the Surgical Stress Response and Improves Long-term Cancer-specific Survival. PMID 37184246 · Surg Laparosc Endosc Percutan Tech · 2023-Jun-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial. PMID 37079324 · JAMA Oncol · 2023-Jun-01 The study is a randomized Phase 3 oncology trial with human patients and original results, but it does not meet two key eligibility criteria: it compares two radiation techniques (no drug intervention), and its primary endpoint is a patient-reported pain response at 3 months, which is not a time-to-event efficacy endpoint like OS or PFS. Therefore, it is excluded.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimal postoperative surveillance strategies for cancer survivors with gastric neuroendocrine carcinoma based on individual risk: a multicenter real-world cohort study. PMID 37076132 · Int J Surg · 2023-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Quality-of-Life and Recurrence Outcomes Following Laparoscopic Elective Sigmoid Resection vs Conservative Treatment Following Diverticulitis: Prespecified 2-Year Analysis of the LASER Randomized Clinical Trial. PMID 37074706 · JAMA Surg · 2023-Jun-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial. PMID 37043210 · JAMA Surg · 2023-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. PMID 37022706 · JAMA Oncol · 2023-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. PMID 37022702 · JAMA Oncol · 2023-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). PMID 37018649 · J Clin Oncol · 2023-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. PMID 36892847 · JAMA Oncol · 2023-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Simple Aspiration versus Drainage for Complete Pneumothorax: A Randomized Noninferiority Trial. PMID 36693146 · Am J Respir Crit Care Med · 2023-Jun-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women. PMID 36637153 · Int J Cancer · 2023-Jun-01 The study is a randomized, human, oncology-related trial with a drug intervention. However, it is a dose-finding substudy (not Phase III/IIIb or Phase II/III) and lacks any time-to-event efficacy endpoint (OS, PFS, DFS, etc.), focusing instead on histological and density changes in normal breast tissue of healthy women for primary prevention mechanisms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor. PMID 36485007 · Clin Cancer Res · 2023-Jun-01 The record describes an original, randomized, placebo-controlled Phase II trial (INVICTUS) with a primary PFS endpoint, but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided abstract/metadata, so eligibility cannot be definitively confirmed. It meets all other criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial. PMID 39170825 · Chin Med J Pulm Crit Care Med · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma. PMID 37401306 · Eur Rev Med Pharmacol Sci · 2023-Jun The study is a randomized, oncology, human trial with a drug intervention and time-to-event endpoints, but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided information. The deterministic review signal indicates 'phase3_evidence_unclear'. Without explicit phase information, the record cannot be confirmed as meeting the definitive phase criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments. PMID 37401302 · Eur Rev Med Pharmacol Sci · 2023-Jun The record is a review article discussing emerging treatments, not an original result report of a specific randomized Phase III or Phase II/III trial. It lacks a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anthracyclines and Biomarkers of Myocardial Injury: The Effect of Remote Ischemic Conditioning. PMID 37397080 · JACC CardioOncol · 2023-Jun The study is a randomized trial in oncology patients with a drug intervention (anthracyclines) and reports time-to-event endpoints (MACE and cancer death). However, it is not a Phase III or Phase II/III definitive trial, and the primary endpoint is a biomarker of cardiotoxicity, not a key efficacy endpoint like OS or PFS. The trial is focused on cardioprotection, not cancer treatment efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -